Neuropharmacological treatment of mental dysfunction in Parkinson's disease

Patrick McNamara, Raymon Durso

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations

Abstract

Many patients with Parkinson's Disease (PD) experience significant cognitive and mood impairment -even early in the course of the disease. These mental impairments are only partially responsive to levodopa treatment and are often as disabling as the motor impairment, particularly in mid and late stages of the disease. Investigators have recently begun a search for new agents that can effectively treat mental dysfunction of PD. Although there have been only a handful of properly controlled clinical trials of interventions targeted at amelioration of mental dysfunction in PD, progress has been made. Based on the available evidence, targeting catecholaminergic and cholinergic function may be an effective strategy for amelioration of cognitve, mood and psychiatric disturbances in PD.

Original languageEnglish (US)
Pages (from-to)43-51
Number of pages9
JournalBehavioural Neurology
Volume17
Issue number1
DOIs
StatePublished - 2006
Externally publishedYes

Fingerprint Dive into the research topics of 'Neuropharmacological treatment of mental dysfunction in Parkinson's disease'. Together they form a unique fingerprint.

Cite this